NCT04375878 - OPTION 2: A Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Cystic Fibrosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 20, 2020

Primary Completion Date

April 8, 2021

Study Completion Date

April 8, 2021

Conditions

Exocrine Pancreatic Insufficiency (EPI)Cystic Fibrosis (CF)

Interventions

DRUG

MS1819

MS1819 in enteric capsules. It contains is a yeast-derived (non-porcine) lipase pancreatic enzyme replacement.

DRUG

Porcine PERT

Porcine PERT is being used a comparator to MS1819 as a second drug/intervention.

Trial Locations (15)

Investigator Site 106, Hershey

Investigator Site 102, Altamonte Springs

Investigator Site 107, Miami

Investigator Site 104, Toledo

Investigator Site 110, Cleveland

Investigator Site 101, Glenview

Investigator Site 111, Wichita

Investigator Site 103, Las Vegas

Investigator Site 105, Long Beach

Investigator Site 108, Portland

Investigator Site 205, Bialystok

Investigator Site 203, Karpacz

Investigator Site 206, Katowice

Investigator Site 202, Rabka-Zdrój

Investigator Site 204, Sopot